Inefficient cytotoxic T lymphocyte-mediated killing of HIV-1-infected cells in vivo

PLoS Biology
Becca AsquithA R McLean

Abstract

Understanding the role of cytotoxic T lymphocytes (CTLs) in controlling HIV-1 infection is vital for vaccine design. However, it is difficult to assess the importance of CTLs in natural infection. Different human leukocyte antigen (HLA) class I alleles are associated with different rates of progression to AIDS, indicating that CTLs play a protective role. Yet virus clearance rates following antiretroviral therapy are not impaired in individuals with advanced HIV disease, suggesting that weakening of the CTL response is not the major underlying cause of disease progression and that CTLs do not have an important protective role. Here we reconcile these apparently conflicting studies. We estimate the selection pressure exerted by CTL responses that drive the emergence of immune escape variants, thereby directly quantifying the efficiency of HIV-1-specific CTLs in vivo. We estimate that only 2% of productively infected CD4+ cell death is attributable to CTLs recognising a single epitope. We suggest that CTLs kill a large number of infected cells (about 10(7)) per day but are not responsible for the majority of infected cell death.

References

Jun 1, 1974·Klinische Wochenschrift·F Trepel
Jun 20, 1995·Proceedings of the National Academy of Sciences of the United States of America·M J Bevan, T J Braciale
Apr 5, 1996·Science·M A Nowak, C R Bangham
Dec 24, 1996·Proceedings of the National Academy of Sciences of the United States of America·P KlenermanM A Nowak
Mar 4, 1997·Proceedings of the National Academy of Sciences of the United States of America·D A PriceR E Phillips
Mar 1, 1997·Nature Medicine·A M ChinnaiyanG J Nabel
Jan 1, 1997·Annual Review of Immunology·A J McMichael, R E Phillips
Mar 1, 1997·Current Biology : CB·M B Feinberg, A R McLean
Mar 3, 1999·Proceedings of the National Academy of Sciences of the United States of America·A G RodrigoJ I Mullins
Jan 11, 2000·Journal of Virology·A E JetztJ P Dougherty
Jul 6, 2000·The Journal of Experimental Medicine·V AppayS L Rowland-Jones
Sep 6, 2000·Proceedings. Biological Sciences·R A ArnaoutD Wodarz
Apr 3, 2002·Nature Medicine·Victor AppaySarah L Rowland-Jones
Aug 6, 2002·Current Opinion in Microbiology·Paul KlenermanRodney Phillips
Sep 10, 2002·The Journal of Immunology : Official Journal of the American Association of Immunologists·Ana E SousaRui M M Victorino
Jan 15, 2003·Annual Review of Medicine·Mary Carrington, Stephen J O'Brien
Jul 29, 2003·European Journal of Immunology·Derek C MacallanPeter C Beverley
Sep 17, 2003·The Journal of Clinical Investigation·Guido Silvestri, Mark B Feinberg
Nov 11, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·Beth D JamiesonSteven Wolinsky
Feb 11, 2004·Nature Medicine·A J LeslieP J R Goulder
Apr 7, 2004·The Journal of Experimental Medicine·Rika DraenertPhilip J R Goulder

❮ Previous
Next ❯

Citations

Apr 5, 2014·PLoS Computational Biology·Marjet ElemansBecca Asquith
Apr 4, 2007·Proceedings of the National Academy of Sciences of the United States of America·Becca Asquith, Angela R McLean
Jan 15, 2014·Journal of Theoretical Biology·Carmen Lía MurallChris T Bauch
Jan 24, 2007·Proceedings of the National Academy of Sciences of the United States of America·Roland R RegoesRustom Antia
Nov 28, 2014·Proceedings. Biological Sciences·Carmen Lía MurallTroy Day
Oct 2, 2014·Journal of Pharmacokinetics and Pharmacodynamics·Dominik Wodarz
Apr 11, 2006·PLoS Computational Biology·Vitaly V Ganusov, Rob J De Boer
Jun 23, 2006·PLoS Computational Biology·Sergei L Kosakovsky PondAndrew J Leigh Brown
Apr 12, 2007·Journal of the Royal Society, Interface·Marc Lipsitch, Justin J O'Hagan
Dec 13, 2007·PloS One·Andrew YatesRustom Antia
Jul 19, 2008·PLoS Computational Biology·Christian L Althaus, Rob J De Boer
Jun 3, 2009·The Journal of Experimental Medicine·Nilu GoonetillekeAndrew J McMichael
Aug 22, 2009·PLoS Computational Biology·Frederik Graw, Roland R Regoes
Dec 17, 2009·Nature Reviews. Immunology·Andrew J McMichaelBarton F Haynes
Feb 4, 2010·PLoS Computational Biology·Richard A Neher, Thomas Leitner
Nov 17, 2010·PLoS Computational Biology·Ulrich D Kadolsky, Becca Asquith
Dec 3, 2010·PLoS Pathogens·Helen R FryerAngela R McLean
Mar 26, 2011·Proceedings of the National Academy of Sciences of the United States of America·Rebecca BatorskyJohn M Coffin
Oct 13, 2011·PLoS Computational Biology·Marjet ElemansBecca Asquith
Jan 3, 2012·Genetics·Jack da Silva
Jun 2, 2012·PLoS Computational Biology·Rafal MostowySebastian Bonhoeffer
Sep 12, 2013·BMC Biology·Alan S Perelson, Ruy M Ribeiro
Nov 19, 2013·PLoS Pathogens·Nafisa-Katrin Seich Al BasatenaBecca Asquith
Jan 16, 2007·Annual Review of Medicine·Andrew A Lackner, Ronald S Veazey
Mar 21, 2007·Immunology and Cell Biology·Becca Asquith, Charles R M Bangham
Apr 11, 2007·Immunology and Cell Biology·Roland R RegoesRustom Antia
Apr 12, 2012·Proceedings. Biological Sciences·Christian L Althaus, Rob J De Boer
Apr 7, 2012·Journal of Theoretical Biology·Sarah M Roy, Dominik Wodarz
Mar 23, 2011·Journal of Theoretical Biology·Tinevimbo Shiri, Alex Welte
Nov 26, 2009·Mathematical Biosciences·Isaac Chun-Hai FungGeoffrey P Garnett
Nov 17, 2009·Journal of Theoretical Biology·R A SergeevI M Rouzine
Nov 29, 2007·Trends in Immunology·Becca Asquith, Charles R M Bangham
Aug 19, 2015·Immunology Letters·Saikrishna GadhamsettyRob J de Boer

❮ Previous
Next ❯

Software Mentioned

Escape

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.